» Articles » PMID: 10857966

Similar 9-year Mortality Risks and Reproducibility for the World Health Organization and American Diabetes Association Glucose Tolerance Categories: the Hoorn Study

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 2000 Jun 17
PMID 10857966
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare the risks of all-cause and cardiovascular disease (CVD) mortality in the American Diabetes Association (ADA) and World Health Organization (WHO) glucose tolerance categories after 9 years of follow-up in the Hoorn Study and to study the test-retest reproducibility of those categories.

Research Design And Methods: In this population-based cohort study of 2,468 elderly men and women, subjects were classified according to both the WHO and the ADA criteria. Causes of death were extracted from the medical records. Age- and sex-adjusted relative risks were estimated by Cox's proportional hazards model. Reproducibility of the diagnostic criteria was assessed in a sample of 1,109 subjects with duplicate oral glucose tolerance tests.

Results: Subjects with known diabetes had a four to five times higher risk of all-cause and CVD mortality compared with normal subjects (P<0.05). The relative risks of all-cause mortality were 1.67 (95% CI 1.09-2.57) and 1.56 (1.00-2.43) for newly diagnosed diabetic subjects according to the WHO and ADA criteria, respectively. The WHO and ADA criteria had similar levels of reproducibility The overall K was 0.59 (0.54-0.64) for WHO criteria and 0.61 (0.56-0.66) for ADA criteria. For the category of newly diagnosed diabetes according to WHO or ADA, the percentages of agreement for the second test compared with the first test were 77% (85/110) and 74% (74/100), respectively.

Conclusions: Both sets of diagnostic criteria identify criteria-specific diabetic subjects with an increased mortality risk compared with normal subjects, and the reproducibility of both criteria is similar.

Citing Articles

Efficacy and Safety of Prescription Omega-3 Fatty Acids Added to Stable Statin Therapy in Korean Patients with Type 2 Diabetes and Hypertriglyceridemia: a Randomized Controlled Trial.

Son J, Kim C, Nam M, Park I, Yoo S J Lipid Atheroscler. 2020; 8(2):221-231.

PMID: 32821712 PMC: 7379108. DOI: 10.12997/jla.2019.8.2.221.


Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Richter B, Hemmingsen B, Metzendorf M, Takwoingi Y Cochrane Database Syst Rev. 2018; 10:CD012661.

PMID: 30371961 PMC: 6516891. DOI: 10.1002/14651858.CD012661.pub2.


Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants.

Lancet Diabetes Endocrinol. 2015; 3(8):624-37.

PMID: 26109024 PMC: 4673089. DOI: 10.1016/S2213-8587(15)00129-1.


Predictive Power for Type 2 Diabetes Mellitus using Dynamic Change of Metabolic Syndrome, Dynamic Change of Fasting Plasma Glucose, Metabolic Syndrome and Fasting Plasma Glucose.

Zhou H, Yang C, Dong C, Guo Z, Hu X, Xu Y Iran J Public Health. 2015; 43(4):432-40.

PMID: 26005653 PMC: 4433724.


Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes.

Son J, Kim D, Lee C, Oh S, Song K, Jung C J Diabetes Investig. 2014; 4(5):466-74.

PMID: 24843697 PMC: 4025110. DOI: 10.1111/jdi.12074.